A warm welcome to our new board members, Dr Oliver Hardick of M Ventures and Chris Major of BioProcess 360 Partners.
Oliver is Entrepreneur in Residence in the Biotechnology team at M Ventures, with a focus on life science tools & technology innovation. Having founded Puridify, a biotech tools company which he led as CEO through VC funding to a strong exit by GE Healthcare in 2017, he brings core expertise in the field of bioprocessing, and a broad interest in life sciences & manufacturing technologies.
Chris is a is a serial entrepreneur and Founding Partner of BioProcess360. He has more than 20 years of bioprocessing experience, in both upstream and downstream technologies. He created and led the Purolite Bioprocessing Division from 2015 to a multi-billion-dollar acquisition by Ecolab in 2021. His first start up was WAVE Bioreactors (acquired by GE Healthcare in 2007) where he helped drive the adoption of single-use technology.
“I am delighted to welcome Oliver and Chris, experienced industry veterans with exceptional knowledge of bioprocessing, to our Board of Directors.” said Ruizhi Wang, CEO, Abselion.
Oliver and Chris join existing Directors Luke Rajah of BGF, Ruizhi Wang (CEO), Anne Jones (Non-executive director) and Simon Douglas (Chairman) to form the Company’s new Board of Directors.
Learn more about the Abselion Board of Directors